- Home
- FFIN vs SRRK Comparison
FFIN vs SRRK Comparison
Compare FFIN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFIN | SRRK |
|---|---|---|
| Founded | 1890 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FFIN | SRRK |
|---|---|---|
| Price | $31.67 | $45.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $38.33 | ★ $47.00 |
| AVG Volume (30 Days) | 630.4K | ★ 2.0M |
| Earning Date | 01-22-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 16.54 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $581,881,000.00 | N/A |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $6.75 | $20,271.77 |
| P/E Ratio | $18.65 | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $29.80 | $22.71 |
| 52 Week High | $41.83 | $46.98 |
Technical Indicators
Market Signals| Indicator | FFIN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 69.45 |
| Support Level | $30.92 | $39.51 |
| Resistance Level | $31.85 | $46.32 |
| Average True Range (ATR) | 0.69 | 2.15 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 80.34 | 91.34 |
Price Performance
Historical ComparisonAbout FFIN First Financial Bankshares Inc.
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.